



10/12/04 DT03 Rec' ST/PTO 08 OCT 2004 PCH

Attorney Docket No. 61646 (70904)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SHIOZAWA et al.

U.S.S.N.: 10/501,259

Examiner: Not Yet Assigned

Filed: July 9, 2004

Group: Not Yet Assigned

For: DISEASE SUSCEPTIBILITY GENE FOR RHEUMATOID ARTHRITIS, PROTEIN THEREOF, EVALUATION METHOD AND EVALUATION KIT FOR EVALUATING ONSET POSSIBILITY OF RHEUMATOID ARTHRITIS BY USING THOSE, AND REMEDY AND CURING MEDICINE FOR RHEUMATOID ARTHRITIS

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 and designated by the "Express Mail" mailing label No. EV 437 819 491 US on October 8, 2004.

By

Judy Daley
Judy Daley

Mail Stop Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages);
3. Full Copies of References for IDS (24 references)
4. Copy of International Search Report; and
5. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any excess fees that may be required, or credit any overpayment to Deposit Account No. 04-1105. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: October 8, 2004

By:

Jennifer K. Rosenfield

Jennifer K. Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444

Customer No. 21,874



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SHIOZAWA et al.

U.S.S.N.: 10/501,259

Examiner: Not Yet Assigned

Filed: July 9, 2004

Group: Not Yet Assigned

For: DISEASE SUSCEPTIBILITY GENE FOR RHEUMATOID ARTHRITIS,
PROTEIN THEREOF, EVALUATION METHOD AND EVALUATION KIT
FOR EVALUATING ONSET POSSIBILITY OF RHEUMATOID ARTHRITIS
BY USING THOSE, AND REMEDY AND CURING MEDICINE FOR
RHEUMATOID ARTHRITIS

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 and designated by the "Express Mail" mailing label No. EV 437 819 491 US on October 8, 2004.

By

Judy Daley
Judy Daley

Mail Stop Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
- _____ (2) within three months of the mailing date of the Written Opposition issued by the Japanese Patent Office); or

- _____ (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- _____ (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

- X are enclosed herewith, except that copies of certain U.S. patents and patent publications are not enclosed; or
- _____ have been cited in the parent application, and are thus not being resubmitted herein;
- X Copy of International Search Report.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.


Date: October 8, 2004

Customer No. 21,874

BOS2_450890.1

Respectfully submitted,

By: _____


Jennifer K. Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

61646 (70904)

SERIAL NO.

10/501,259


APPLICANT(S): SHIOZAWA et al.

FILING DATE:

July 9, 2004

ART UNIT:

Not Yet Known



UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
	A1	6,623,924	9/23/03				
	A2	2004-0013655 A1	1/22/04				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	A3	WO 02/055692 A2	18.07.2002	PCT	A61K	31/713	Y
	A4	1 164 190 A1	19.12.2001	EP	C12N	15/12	Y
	A5	WO 00/64946	02.11.2000	PCT	C07K	16/0	Y
	A6	1 008 648 A1	14.06.2000	EP	C12N	15/11	Y
	A7	WO 00/02587	20.01.2000	PCT	A61K	47/48	Y
	A8	WO 96/31598	10.10.1996	PCT	C12N	15/00	Y
	A9	WO 96/20213	04.07.96	PCT	C07K	14/435	Y

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

A10	Davis et al., "Human angiotensinogen-converting enzyme 1 mRNA, complete cds.", Database GenBank Accession No. U83508 (March 26, 1997)
A11	Shiozawa et al., "Studies on the pathogenesis of autoimmune diseases from the viewpoint of the disease susceptibility genes" 21(1)30-35 (2003)
A12	Shiozawa et al., "The molecular genetics of rheumatoid arthritis disease gene", p 2269-2275 (2002)
A13	Shiozawa et al., "Identification of the gene loci that predispose to rheumatoid arthritis", Int'l Immunology 10(12):1891-1895 (1998)
A14	Shiozawa et al., "An approach to identify new genes in autoimmune diseases: lessons from rheumatoid arthritis", Ref. Immunogenet., 2(1):133-139 (2000)

Examiner:

Date:

FORM PTO-1449		ATTY DOCKET NO. 61646 (70904)	SERIAL NO. 10/501,259
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): SHIOZAWA et al.	
		FILING DATE: July 9, 2004	ART UNIT: Not Yet Known
UNITED STATES PATENT DOCUMENTS			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
	A15	Shei Ishikawa, "How to diagnose Rheumatoid Arthritis", Remedy, 73(3):23-27 (1991)	
	A16	Edward D. Harris, Jr., "Rheumatoid Arthritis Pathophysiology and Implications for Therapy", The New England Journal of Medicine" 322(18):1277-1289 (1990)	
	A17	Vyse et al., "Genetic Analysis of Autoimmune Disease", Cell, 85:311-318 (1996)	
	A18	Alisa Erika Koch, "The role of Angiogenesis in rheumatoid arthritis: recent developments", Ann. Rheum. Dis.59(suppl. I)ppi65-i71 (2000)	
	A19	Thurston et al., Angiopoietin-1 protects the adult vasculature against plasma leakage", Nature Medicine, 6(4):460-463 (2000)	
	A20	Masato Nose, "Origin of the Diversity and Similarity of Pathological Manifestations of Collagen Disease", Ryumachi, 40(5):833-848 (2000)	
	A21	Yamamoto et al., "Study on GEM as Causative Gene for Rheumatoid Arthritis (RA)", Ryumachi, 39:445 (1999)	
	A22	Davis et al., "Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning", Cell, 87:1161-1169 (1996)	
	A23	Kruglyak et al., Complete Multipoint Sib-Pair Analysis of Qualitative and Quantitative Traits", Am. J. Hum. Genet., 57:439-454 (1995)	
	A24	Hasegawa et al., "Novel Smooth Muscle Cell Lines form Transgenic Mice Harboring Temperature-sensitive SV40 Larch T-antigen Gene. Temperature dependent Expression of Smooth Muscle Myosin Heavy Chain-1 and Calponin Genes", J. Mol. Cell Cardiol., 29:2177-2186 (1997)	
Examiner:		Date:	